Identifying targets that are expressed on tumor cells but not or lowly expressed in normal cells is crucial for tumor immunity. ROR1 is a highly promising drug target, exhibiting differentiated high expression in various solid tumors and hematologic malignancies, while not expressing in adult healthy tissues. This suggests that ROR1 holds the potential to become […]
At the end of 2020, Genmab and ADC Therapeutics announced the termination of clinical development for Enapotamab vedotin and ADCT-601, respectively, due to their failure to meet expected outcomes in early trials. Both drugs were antibody-drug conjugates (ADCs) targeting AXL. Enapotamab vedotin was coupled with the microtubule inhibitor MMAE, while ADCT-601 was coupled with the […]
As December unfolds, DIMA, a leading biotechnology company, is gearing up for a strong presence at several esteemed international conferences. This engagement underscores DIMA’s commitment to advancing antibody research and presenting groundbreaking developments in CAR-T therapy.
The 5T4 protein, also known as Wnt-activated inhibitory factor 1 (WAIF1) or Trophoblast Glycoprotein (TPBG), is a glycoprotein found in embryonic trophoblast cells. It has been identified as a treatment target for solid tumors due to its abundance in cancerous tissues and limited expression in normal tissues. Currently, there are approximately nine investigational drugs targeting […]
Antibody-drug conjugates (ADCs) mainly consist of monoclonal antibodies, linkers, and cytotoxic payloads. The antibody, acting as the “missile” in ADC drugs, possesses target-specific functionality. It can selectively recognize tumor cell surface antigens, undergo internalization upon binding to these antigens, and deliver the cytotoxic payload to tumor cells to exert its toxic effects. Since not all […]
Tumor-Associated Calcium Signal Transducer 2 (TROP2), also known as TACSTD2 and EGP-1, is a surface antigen found in numerous solid tumors. It has become a pivotal target for pharmaceutical giants spurring a race in drug development in the world. Currently, TROP2-targeting biopharmaceuticals are predominantly concentrated in the Antibody-Drug Conjugate (ADC). Based on incomplete statistics, there are 11 TROP2-targeting […]
Antibody-drug conjugates (ADCs) represent a promising class of targeted therapies in the fight against cancer. These innovative therapies aim to deliver small-molecule chemotherapy agents directly to cancer cells while sparing healthy ones. Since the approval of MYLOTARG in 2000, ADCs have become a vital category in the realm of cancer-targeted treatments, consisting of three key […]
In 2012, a young girl named Emily Whitehead, suffering from acute lymphoblastic leukemia, became the first child to undergo second-generation CD19 CAR-T cell therapy by Dr. Carl June, a scientist in Pennsylvania. Her successful treatment marked a historic milestone in the world of medicine. It brought “CAR-T cell immunotherapy,” a revolutionary approach in the fight […]
In 1986, the world’s first monoclonal therapeutic drug, Orthoclone (OKT3), was approved by the FDA for its use in preventing rejection reactions during organ transplantation. Since then, antibody drugs have started gaining traction and incited an increasing number of research in this area. By the end of January 2023, the FDA has approved 119 antibody […]
Human carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), initially discovered in colon cancer by Gold and Freeman in 1965 [1] [2], has long served as a pivotal tumor marker for clinical detection and diagnosis of colorectal cancer. Recent advancements in CEACAM5 research have unveiled its potential as a target for developing novel cancer therapeutics. Notably, […]